T2844

Hyperoside (Hyperin) is a naturally occuring flavonoid compound which shows multiple bioactivities, including myocardial protection, anti-redox, and anti-inflammatory activities.

PPI-1019 is an APP (β-amyloid A4) inhibitor for the treatment of neurological disorders and the study of Alzheimer's disease (AD).

PPD 10558, a HMG-CoA reductase inhibitor, is used potentially for treatment of primary hypercholesterolemia.

PQ-69 is a selective adenosine A1 receptor antagonist with inverse agonist activity.

PR-104A is a hypoxia-targeted anticancer agent.

PR5-LL-CM01 is an effective epigenetic modulator and histone deacetylase (HDAC) inhibitor. It alters chromatin structure and activates tumor suppressor gene transcription by increasing histone acetylation, showing significant anti-proliferative activity in solid tumor models.

Pradefovir (Remofovir) is a reverse transcriptase inhibitor potentially for treatment of chronic HBV infection. Pradefovir is also a liver-targeted prodrug of adefovir. After metabolic activation, Pradefovir was converted to PMEA (9-(2-phosphonylmethoxyethyl)adenine) in human liver microsomes with a K(m) of 60 microM, a maximum rate of metabolism of 228 pmol/min/mg protein, and an intrinsic clearance of about 359 ml/min.